SLC5A2 and hepatocellular carcinoma: However, there was no association observed between use of SGLT-2 inhibitors and hepatic encephalopathy (HR, 0.99 [95% CI, 0.89-1.09]; E-value 1.16) and HCC (HR, 0.95 [95% CI, 0.85-1.06]; E-value, 1.32) between the 2 groups.